Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
cAMP signaling tools act on the second messenger cyclic AMP and on the proteins that read its signal. Cyclic adenosine monophosphate (cAMP) forms when receptors coupled to stimulatory G proteins activate adenylyl cyclases. In 1968, a cAMP-dependent enzyme, now called protein kinase A (PKA), was purified from rabbit skeletal muscle. Exchange proteins directly activated by cAMP (Epac), reported in 1998, activate the small guanosine triphosphatase (GTPase) Rap1. Sp-5,6-DCl-cBIMPS and cAMPS-Sp are cell-permeant cAMP analogs that activate PKA directly. ESI-09 blocks Epac1 and Epac2, whereas ESI-05 is selective for Epac2. SQ22536 lowers cAMP production in cells by inhibiting adenylyl cyclase activity. The Adenylyl Cyclase category covers the enzymes that synthesize the messenger.
Sp-5,6-DCl-cBIMPS is a potent activator of cAMP-dependent protein kinases (cAMP-PK). This compound effectively stimulates insulin release and has been shown to inhibit U-46619-induced activation of Rho, Gq, and G12/G13 in platelets. It serves as a valuable tool for investigating signaling pathways related to cAMP and its role in cellular physiology and metabolic regulation.
Synonyms: Sp-5,6-DCI-cBIMPS
Sp-5,6-DCl-cBIMPS sodium is a potent activator of cAMP-dependent protein kinases (cAMP-PK), facilitating enhanced insulin release. This compound also inhibits the U-46619-induced activation of Rho, Gq, and G12/G13 in platelets, making it a valuable tool for investigating signaling pathways related to platelet function and insulin modulation. Research applications include studies on metabolic regulation and cardiovascular responses linked to cAMP signaling.
